$1.17 BillionThe market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.
-Total revenue in the last quarter.
$-36.3 MillionNet income is all revenues minus all expenses including taxes and interest in the last quarter.
$-1.75Earnings per share is the amount of net income that is attributed to each single share outstanding.
-Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).
-9.05xThe price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.
$-21.3 MillionEarnings before interest expenses and taxes in the last quarter.
93The number of full time employees.
Translate Bio, Inc. engages in the research and development of therapeutic drugs. It focuses on developing medicines to treat diseases caused by protein or gene dysfunction. Its lead product candidates include MRT5005 for the treatment of cystic fibrosis; and for the treatment of ornithine transcarbamylase deficiency. The company was founded by Arthur M. Krieg and Jeannie T. Lee in 2011 and is headquartered in Lexington, MA.
LOS ANGELES--(BUSINESS WIRE)---- $TBIO #TBIO--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Translate Bio, Inc.Business Wire, 3 months ago
Biotech stocks went on a seesaw ride along with the broader markets in the week ended June 26. Yet there were some encouraging developments on the COVID-19 vaccine development front. Vaccine compan...Benzinga, 4 months ago
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 23) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Accele...Benzinga, 4 months ago